Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812377 | 1.00 | MAPT (0.39) | MAPTABCB1L3MBTL1ALDH1A1APOBEC3A | |
| SCHEMBL18501522 | 1.00 | MAPT (0.39) | MAPTABCB1L3MBTL1ALDH1A1APOBEC3A | |
| Hydrochloric Acid SCHEMBL28694145 | 0.98 | MAPT (0.38) | MAPTABCB1L3MBTL1ALDH1A1APOBEC3A | |
| SCHEMBL7766360 | 0.83 | SOAT1 (0.41) | MAPTABCB1L3MBTL1ALDH1A1APOBEC3A | |
| SCHEMBL7766372 | 0.83 | SOAT1 (0.41) | MAPTABCB1L3MBTL1ALDH1A1APOBEC3A | |
| SCHEMBL7766368 | 0.83 | SOAT1 (0.41) | MAPTABCB1L3MBTL1ALDH1A1APOBEC3A | |
| SCHEMBL2914885 | 0.83 | ALDH1A1 (0.46) | MAPTABCB1L3MBTL1ALDH1A1APOBEC3A | |
| SCHEMBL10418171 | 0.81 | ABCB1 (0.40) | MAPTABCB1ALDH1A1NPSR1GLO1 | |
| SCHEMBL8626482 | 0.81 | ABCB1 (0.36) | MAPTABCB1ALDH1A1NPSR1GLO1 | |
| SCHEMBL10418169 | 0.81 | ABCB1 (0.40) | MAPTABCB1ALDH1A1NPSR1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114031575-B | Preparation method of ethyl northioxomate | 山东金城医药化工有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-114014823-B | Preparation method of trans-northioxomate ethyl ester | 山东金城医药化工有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-114031575-A | Preparation method of ethyl noraminothiazoly loximate | 山东金城医药化工有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-114014823-A | Preparation method of trans-ethyl noraminothiazolyloximate | 山东金城医药化工有限公司 | 2022-02-08 | — | — | CN | claimed |
| CN-110642805-A | Synthetic method of ethyl aminothiazoly loximate | 安徽金禾实业股份有限公司 | 2020-01-03 | — | — | CN | claimed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024153155-A1 | DOUBLE-HETEROCYCLIC WRN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都微芯药业有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-114031575-B | Preparation method of ethyl northioxomate | 山东金城医药化工有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-114031575-B | Preparation method of ethyl northioxomate | 山东金城医药化工有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-4203899-A | Thiazolylacetamido compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-05-20 | — | — | US | disclosed |
| US-4202893-A | Alkyloximes of 7-amino-thiazolyl-acetamido-cephalosporanic acids | ROUSSEL UCLAF (FR) | 1980-05-13 | — | — | US | disclosed |
| EP-0009671-A2 | Starting compounds for preparing cephem compounds and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-16 | — | — | EP | disclosed |
| US-4196205-A | ANTIBIOTICS, BACTERICIDES | ROUSSEL UCLAF (FR) | 1980-04-01 | — | — | US | disclosed |
| US-4152432-A | ANTIBIOTICS | ROUSSEL UCLAF (FR) | 1979-05-01 | — | — | US | disclosed |
| US-4098888-A | THIAZOLYLACETAMIDO CEPHALOSPORIN TYPE COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1978-07-04 | — | — | US | disclosed |
| US-4071531-A | Oxathiino- and dithiino-aminoacetic acids | RHONE-POULENC INDUSTRIES (FR) | 1978-01-31 | — | — | US | disclosed |
| US-4029781-A | BACTERICIDES | RHONE-POULENC INDUSTRIES (FR) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | MAPT 389/4885ABCB1 2923/4885L3MBTL1 3015/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | MAPT 383/4885ABCB1 2939/4885L3MBTL1 3016/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | MAPT 389/4885ABCB1 2923/4885L3MBTL1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.